Page last updated: 2024-08-24

gemcitabine and oblimersen

gemcitabine has been researched along with oblimersen in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benimetskaya, L; Hua, E; Khvorova, A; Lai, JC; Miller, P; Stein, CA; Wu, S; Zhang, LM	1
Benimetskaya, L; Miller, P; Stein, CA	1
Advani, RH; Fisher, GA; Francisco, B; Galatin, PS; Julian, T; Losa, R; Sierra, MI; Sikic, BI	1

Trials

1 trial(s) available for gemcitabine and oblimersen

Article	Year
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Investigational new drugs, 2011, Volume: 29, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Genes, bcl-2; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Oligonucleotides, Antisense; Thionucleotides; Treatment Outcome	2011

Article

Year

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.

Investigational new drugs, 2011, Volume: 29, Issue:5

Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Genes, bcl-2; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Oligonucleotides, Antisense; Thionucleotides; Treatment Outcome

2011

Other Studies

2 other study(ies) available for gemcitabine and oblimersen

Article	Year
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured	2004
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC. Oligonucleotides, 2005,Fall, Volume: 15, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides	2005

Article

Year

Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24

Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured

2004

518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.

Oligonucleotides, 2005,Fall, Volume: 15, Issue:3

Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides

2005